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Abstract
Ulcerative colitis increases colorectal cancer risk by mechanisms that remain incompletely
understood. We approached this question by determining the genetic and epigenetic pro-
files of colitis-associated colorectal carcinomas (CA-CRC). The findings were compared to
Lynch syndrome (LS), a different form of cancer predisposition that shares the importance
of immunological factors in tumorigenesis. CA-CRCs (n = 27) were investigated for micro-
satellite instability, CpG island methylator phenotype and somatic mutations of 999 can-
cer-relevant genes (“Pan-cancer” panel). A subpanel of “Pan-cancer” design (578 genes)
was used for LS colorectal tumors (n = 28). Mutational loads and signatures stratified CA-
CRCs into three subgroups: hypermutated microsatellite-unstable (Group 1, n = 1), hyper-
mutated microsatellite-stable (Group 2, n = 9) and nonhypermutated microsatellite-stable
(Group 3, n = 17). The Group 1 tumor was the only one with MLH1 promoter
hypermethylation and exhibited the mismatch repair deficiency-associated Signatures
21 and 15. Signatures 30 and 32 characterized Group 2, whereas no prominent single sig-
nature existed in Group 3. TP53, the most common mutational target in CA-CRC (16/27,
59%), was similarly affected in Groups 2 and 3, but DNA repair genes and Wnt signaling
genes were mutated significantly more often in Group 2. In LS tumors, the degree of
hypermutability exceeded that of the hypermutated CA-CRC Groups 1 and 2, and
somatic mutational profiles and signatures were different. In conclusion, Groups 1 (4%)
and 3 (63%) comply with published studies, whereas Group 2 (33%) is novel. The exis-
tence of molecularly distinct subgroups within CA-CRC may guide clinical management,
such as therapy options.
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1 | BACKGROUND
Inflammatory bowel disease, comprising ulcerative colitis (UC) and
Crohn's disease, is associated with an increased risk of colorectal
Abbreviations: CA-CRC, colitis-associated colorectal carcinoma; CCP, Comprehensive Cancer
Panel; CIMP, CpG island methylator phenotype; CRC, colorectal carcinoma; LS, Lynch
syndrome; MMR, DNA mismatch repair; MSI, microsatellite instability; MSI-H, high-degree
microsatellite instability; MS-MLPA, methylation-specific multiplex ligation-dependent probe
amplification; MSS, microsatellite-stable; UC, ulcerative colitis; VAF, variant allele frequency.
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carcinoma (CRC).1 UC-associated CRC (CA-CRC) develops in a multi-
factorial manner involving a complex imbalance of regulation and
coordination of the human immune system, gut microbial composition
and epithelial regeneration during the persistent inflammatory
period.1,2 Inflammation together with no mucosal healing predisposes
to CA-CRC via inflammation-dysplasia-carcinoma sequence.2 During
inflammation-associated tumorigenesis, active inflammatory cells pro-
duce reactive oxygen species and reactive nitrogen intermediates,
which induce mutations leading to genetic instability.3 Cytokine pro-
duction further enhances intracellular reactive oxygen species and
reactive nitrogen intermediates in a malignant cell; moreover, it pro-
motes epigenetic modifications that can accelerate tumor initiation by
silencing DNA repair genes, for example.3
Up to 35% of CRC risk can be attributed to genetic factors, and
some 5% of CRC cases represent hereditary single-gene disorders.4
Germline defects in DNA mismatch repair (MMR) genes MLH1, MSH2,
MSH6 and PMS2,5 or more rarely deletions in the 30 end of EPCAM gene
leading to hypermethylation of MSH2 gene promoter,6 cause Lynch syn-
drome (LS), the most prevalent form of hereditary CRC. Heterozygous
germline defects lead to reduced levels of functional MMR proteins,
which increases the risk for early-onset cancers, primarily CRC and endo-
metrial cancer.7 CRC in LS often, but not always, develops via the
adenoma-carcinoma sequence.8 The emergence of de novo somatic
mutations contributes to high levels of neoantigens, which are thought
to result in immune activation and later, immune evasion.9 Thus, in anal-
ogy to CA-CRC, immunological alterations and inflammation accompany
LS-associated colorectal tumorigenesis from the outset.
Recently, genomic analyses on cancers have revealed details of
mutational processes and their timing in various cancers. Characteriza-
tion of such events can be useful to understand molecular mechanisms
of cancers and can help to determine plausible biomarkers for diagnostic
and therapeutic use. In our study, we aim to determine the somatic
mutational profiles and signatures for CA-CRC and compare the findings
to LS-associated colorectal tumors, thereby covering two forms of early-
onset colorectal cancer with different etiologies, but with a strong immu-
nological component as a common denominator.
2 | MATERIALS AND METHODS
2.1 | Patients and samples
The study material consisted of formalin-fixed, paraffin-embedded tissue
specimens from UC patients developing CRC (CA-CRC, n = 27) and LS
patients (verified carriers of pathogenic or likely pathogenic germline vari-
ants of MMR genes) developing colorectal tumors (adenomas with high-
grade dysplasia, n = 10, and CRCs, n = 18). Besides tumor material, we
had the patients' normal colon tissue or blood specimens available. All
the LS patients were represented in the nationwide Lynch Syndrome
Registry of Finland. DNA was extracted using the nonenzymatic proto-
cols, modified extraction protocol of the phenyl-chlorophorm method10
and protocol described in Lahiri and Nurnberger11 for formalin-fixed,
paraffin-embedded and blood samples, respectively.
2.2 | Microsatellite instability analysis
Microsatellite instability (MSI) was assayed using mononucleotide
repeat markers BAT25 and BAT26 that are sensitive and specific
markers of high-degree MSI (MSI-H).12,13 Unstable BAT25 and/or
BAT26 indicated MSI (specifically, MSI-H), whereas tumors in which
both markers were stable were considered microsatellite-stable
(MSS).
2.3 | CpG island methylator phenotype analysis
CpG island methylator phenotype (CIMP) status was assessed with
commercial SALSA methylation-specific multiplex ligation-dependent
probe amplification (MS-MLPA) ME042-B2 (LS samples) and
ME042-C1 (UC samples) probemixes (MRC Holland, Amsterdam, the
Netherlands) according to the manufacturer's protocol, and as
described in Valo et al.14 CIMP status was defined according to the
Weisenberger panel15: a sample was considered CIMP positive when
at least three out of five genes (CACNA1G, IGF2, NEUROG1, RUNX3
and SOCS1) were methylated. A set of corresponding normal samples
were examined to determine a threshold of hypermethylation for each
probe with a stringency level II, details described in Valo et al14 and
values presented in Supplementary Table 1.
2.4 | Parallel sequencing
Sequencing was performed on 27 CA-CRC patients' paired tumor-normal
samples (n = 54) and 28 LS tumors including adenomas with high-grade
dysplasia and carcinomas, paired with the patients' normal tissue samples
(n = 56). Prior to sequencing, the core facility (FIMM) conducted a
LabChip gDNA analysis to evaluate the quality of each sample. CA-CRC
samples were sequenced as follows: sequencing libraries were prepared
using the Twist EF library kit and Twist custom capture kit (Twist
What's new?
Ulcerative colitis-associated colorectal carcinoma (CA-CRC) is a
complex disease involving inflammation-associated tumorigen-
esis and genetic mutation. Despite extensive knowledge of
germline defects linked to CA-CRC, however, molecular patho-
genesis of the disease remains poorly defined. In this study,
using tumor profiling, the authors describe three genetic and
epigenetic CA-CRC subgroups, two of which are previously
known and one that is novel. The novel subgroup consisted of
hypermutated microsatellite-stable tumors, which displayed
distinct mutational signatures compared to the remaining
CA-CRC subgroups and Lynch syndrome tumors, suggesting
pathophysiologic differences. The existence of molecular sub-
groups within CA-CRCs may inform treatment decisions.
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Bioscience, San Francisco, CA). The custom kit called Pan-cancer panel
included probes (n = 17 314) in the regions of 999 cancer-associated
genes totaling a 6.4 Mb design (Supplementary Table 2). The libraries
were sequenced using a S4 cell and run on the NovaSeq platform
(Illumina, San Diego, CA). Average data per sample was 6.4 Gb, and the
average depth of targeted areas was 286. Detailed performance charac-
teristics are given in Supplementary Table 3.
LS samples were sequenced as part of our earlier investigation.16
Briefly, the Nimblegen Comprehensive Cancer Panel (CCP; Roche
Diagnostics, Basel, Switzerland), a 4 Mb design with 578 cancer-
related genes, was used together with ThruPLEX DNA-seq Kit
(Rubicon Genomics, Ann Arbor, MI) for library preparation. Sequenc-
ing was done on the Illumina HiSeq 2500 platform. The mean target
coverage of 41-fold was reached. Details of performance characteris-
tics are described in Porkka et al.16
For both data sets, raw data were processed using an
in-house pipeline called variant calling pipeline version 3.7,17 and
data were aligned to the human genome GRCh38. First, the
adapters were trimmed from the reads as well as any bad quality
nucleotides from the beginning or the end of the reads, removing
any pair having read(s) smaller than 36 bp. Reads were then
aligned to the GRCh38 reference genome with the BWA (version
0.6.2). Nonunique read pairs and nonunique single reads were
removed and GATK (version 3.7) BaseRecalibrator was used to
clean the alignment. Any potential PCR duplicates were removed
using Picard (version 2.9.0). MarkDuplicates and GATK Inde-
lRealigner were used for indel sites.
2.5 | Somatic mutation analysis
Paired tumor-normal data were compared and nonsynonymous
somatic mutations (missense, nonsense, frameshift, in-frame coding
deletion/insertion and splice site mutations) were extracted using the
VarScan2 version 2.3.2. The following parameters and thresholds
were applied: strand-filter 1, min-coverage-normal 8, min-coverage-
tumor 6, somatic-P-value 1, normal-purity 1 and min-var-freq 0.05.
Mutations were annotated using SnpEff version 4.0 with the Ensembl
v86 annotation database. Misclassified germline variants were filtered
out using the Database of Single Nucleotide Polymorphisms and com-
mon population variants were removed. Mutational signatures were
extracted from somatic nonsynonymous mutation data using the
MutationalPatterns package18 in R. Mutation signatures were com-
pared to sixty available single base substitution signatures of the Cata-
logue of Somatic Mutations in Cancer (https://cancer.sanger.ac.uk/
cosmic/signatures/SBS/).19
2.6 | Statistical analysis
Statistical analyses were conducted using the SPSS software, ver-
sion 25.0 (IBM SPSS Inc. Chicago, IL). Fisher's exact test was used
to study pairwise comparisons of categorical variables. Normal
distribution of continuous data was tested using the Shapiro-Wilk
test. As data were largely not normally distributed and sample sizes
were small, continuous variables were analyzed using the nonpara-
metric Mann-Whitney U test. Correlation analyses were calculated
with Spearman's or Pearson's correlation test. Exact two-sided
P values were calculated. P values <.05 were considered statisti-
cally significant.
3 | RESULTS
3.1 | Study design
This investigation was undertaken to define the molecular pathogene-
sis of colorectal tumorigenesis in UC, an idiopathic chronic inflamma-
tory bowel disease with accelerated tumor development by a
“landscaper” mechanism.20 The results were compared to LS, where
impaired “caretaker” function due to inherited (and acquired) MMR
gene defects is known to induce immunological/inflammatory alter-
ations and result in rapid tumor development. Basic characteristics of
the study series are described in Table 1.
3.2 | MSI and CIMP in CA-CRC
Only one CA-CRC tumor showed MSI-H (1/27, 4%). MLH1 promoter
methylation analysis was possible as part of the CIMP MS-MLPA pro-
tocol (see Materials and Methods). The tumor with MSI-H revealed
hypermethylation of the proximal promoter region “C,” which has
been shown to be associated with a loss of MLH1 protein expres-
sion.21 No other CA-CRC tumors had MLH1 promoter methylation,
consistent with stable microsatellites. The Weisenberger criteria15
classified 11/27 (41%) of CA-CRCs as CIMP(+), which corresponds to
the CIMP(+) frequency seen among LS tumors (Table 2). The CIMP
MS-MLPA panel also includes probes for the BRAF Val600Glu muta-
tion, and two CA-CRC tumors (7%) were mutation-positive, compared
to none among LS tumors (Table 2); subsequent panel sequencing
confirmed the results. The single MSI-H CA-CRC tumor did not harbor
BRAF Val600Glu mutation, but it had KRAS Gly12Asp mutation
(Supplementary Table 4).
3.3 | Somatic mutations in CA-CRC
By Pan-cancer panel sequencing, the average rate of nonsynonymous
somatic mutations (VarScan2 somatic P value <.01) was 16.1 muta-
tions/Mb (median 6.3, range 2.8-118.2/Mb) in CA-CRC tumors. Ten
of 27 CA-CRC tumors (37%) were found to be hypermutated (>10
mutations/Mb). These included the single MSI tumor (84.8 mutations/
Mb) and nine MSS tumors (average 29.5 mutations/Mb).
Figure 1 shows the most commonly mutated genes in CA-CRC by
focusing either on genes affected by high-frequency mutations (vari-
ant allele frequency [VAF] at least 25%, which is characteristic of
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colon cancer driver genes),22 or genes involved in at least 30% of
tumors (a cutoff we have used in our previous studies on LS).16 TP53
was the most prominent mutational target in CA-CRC, being affected
with high-frequency mutations in 14 samples out of 27 (52%)
(Figure 1A) and in 18 samples (67%) if any VAF was considered
(Figure 1B). Our VarScan2 annotations were based on the longest
transcript and two TP53 mutations included in Figure 1B were outside
the primary transcript (ENST00000445888.6); 16/27 (59%) samples
had TP53 mutations involving the primary transcript. When VAF
≥25% and involvement in at least 30% of tumors were both required,
only TP53 fulfilled this criterion.
Figure 2 provides a detailed overview of exonic TP53 mutations
present in our CA-CRC tumors. The results are compared to muta-
tions reported in recent investigations on UC or inflammatory bowel
disease23-27 (Figure 2A), and with TP53 mutations detected in our LS
tumors in this investigation (Figure 2B). Our CA-CRC tumors harbored
15 different mutations, mostly located in positions shown to be asso-
ciated with impaired functionality when affected.28 The most frequent
mutation was p.Arg248Trp/Gln occurring in three samples with VAFs
above 25% in all of them. Overall, the vast majority, 73% (11/15) of
TP53 mutations present in CA-CRC were high-frequency somatic
mutations. One was a truncating mutation (p.Tyr205*) found in
one sample (Figure 2A). For comparison, of TP53 mutations present in
LS-associated tumors, only 3/19 (16%) occurred with VAF of 25% or
higher (P = .0013) (Figure 2B).
The total number of nonsynonymous somatic mutations
(VarScan2 P < .01) per CA-CRC tumor did not significantly correlate
with the number of methylated CIMP genes or probes. MMR defi-
ciency explained hypermutability in a single tumor (the one with
MSI described above). To identify possible molecular contributors
for hypermutability in those CA-CRC tumors that were MSS, we
investigated the prevalence of mutations in DNA repair pathway
genes (n = 86) identified by Gene Ontology analysis (www.ebi.ac.
uk/QuickGO). Mutations of DNA repair genes were significantly
enriched in the nine hypermutated MSS cases compared to the
17 nonhypermutated MSS cases of CA-CRC: 142/189 (75%) of
mutations were found in the hypermutant tumors (P = .00001)
(Supplementary Table 5a). By a similar comparison, mutations in
TABLE 1 Characteristics of the patient samples
CA-CRC LS tumors combineda LS HGD adenomas LS carcinomas
P value CA-CRC
vs LS tumors
No. of patients 27 24 10 15 NA
Male sexb 18 (66.7%) 11 (45.8%) 4 (40%) 8 (53.3%) .164
Age at diagnosis, years (mean ± SD)b 51.1 (±10.6) 50.1 (±12.9)c 50.4 (±14)c 50.8 (±12.2) .962
Years of colitis before CRC (mean ± SD)b 22.2 (±10.5)d — — — NA
Gene mutated in the germlineb
MLH1 — 19 (79.2%) 9 (90%) 11 (73.3%) NA
MSH2 — 3 (12.5%) 1 (10%) 2 (13.3%) NA
MSH6 — 2 (8.3%) 0 2 (13.3%) NA
No. of tumors 27 28 10 18 NA
Tumor location
Proximale 12 (44.4%) 15 (53.6%) 2 (20.0%) 13 (72.2%) .380
Distal 12 (44.4%) 12 (42.9%) 8 (100.0%) 4 (22.2%)
NA 3 (11.1%) 1 (3.6%) 0 1 (5.6%)
Stage of carcinomas
I 12 (44.4%) 11 (61.1%) — 11 (61.1%) .354
II 5 (18.5%) 4 (22.2%) — 4 (22.2%)
III 7 (25.9%) 2 (11.1%) — 2 (11.1%)
IV 3 (11.1%) 0 — 0
NA 0 1 (5.6%) — 1 (5.6%)
Note: Note regarding LS samples: Multiple samples were available from three LS patients (three carcinomas, two carcinomas, and a carcinoma plus
adenoma from one patient each). If sampling took place at different time points (metachronous neoplasia), different ages were included in the calculation
of age at diagnosis.
Abbreviations: HGD, high-grade dysplasia; NA, not available or applicable.
aLS-associated adenomas and carcinomas combined.
bCalculated per patients.
cInformation for one case not available.
dInformation for eight cases not available.
eFrom caecum to splenic flexure (included).
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Wnt pathway genes (n = 44 genes) were mostly found in the hyper-
mutated tumors: 115/134 (86%) (P = .00002) (Supplementary
Table 5b). Detailed somatic mutation data for the CA-CRC samples
can be found in Supplementary Table 6.
3.4 | Mutation signatures of CA-CRC tumors
Mutation signature analysis was performed on somatic mutation data






















F IGURE 1 Top mutant genes in
CA-CRC (n = 27 tumors), based on
Pan-cancer panel (n = 999 genes) and
VarScan2 annotations utilizing the longest
RefSeq transcript. A, Selection criteria
were variant allele frequency (VAF) 25% or
higher, and at least 10% of tumors
affected. B, Selection criterion was at least
30% of tumors affected (any VAF was
considered). Asterisk indicates genes that
fulfilled both (A) and (B)-specific criteria
F IGURE 2 Number and distribution of exonic nonsynonymous TP53mutations along the protein domains (transcript ENST00000445888.6; any VAF
was considered). A, Mutations found in our CA-CRC sample set are presented above the bar visualizing the protein domains. Mutations from recent studies
on CA-CRC23-27 are presented below the bar. B, Mutations found in our LS tumor material (n = 28) by CCP sequencing. White circles indicate
nontruncating mutations and black circles refer to truncating mutations. TAD, transactivation domain [Color figure can be viewed at wileyonlinelibrary.com]
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base substitution COSMIC signatures (v3). As evident from Figure 3,
hypermutated and nonhypermutated CA-CRC tumors formed sepa-
rate clusters. The single hypermutated MSI tumor clearly represented
a different signature profile compared to other CA-CRC tumors. The
MSI tumor showed a strong Signature 21 and a notable Signature
15 (Figure 3A), and cosine similarity additionally pinpointed Signature
26 (Figure 3B); all these three signatures are known to be associated
with MSI.29 Hypermutated MSS tumors revealed prominent Signa-
tures 30 and 32 (Figure 3A,B). Additionally, cosine similarity to Signa-
tures 7a and b, 11, 19 and 23 was high (Figure 3B). No single
signature stood out among the nonhypermutated MSS tumors
(Figure 3A,B). In group-wise analysis (Figure 4), comparison of the rel-
ative contributions of mutational signatures between hypermutated
and nonhypermutated MSS CA-CRCs highlighted the predominance
of Signatures 30 and 32 in the former group (relative contributions
36% and 20%, respectively) and the absence of a single dominant sig-
nature in the latter group (with the possible exception of Signature
32 that accounted for 16% of all signature contributions in this group)
(Figure 4A).
3.5 | Molecular comparison of CA-CRC vs LS
tumors
A study protocol analogous to CA-CRCs was applied to LS tumors,
and Table 2 provides a comparative summary of the essential findings.
All LS adenomas had high-grade dysplasia and did not significantly dif-
fer from LS-CRCs with respect to MSI, CIMP or somatic mutational
load (Table 2); therefore, LS adenomas and carcinomas were com-



















































































F IGURE 3 COSMIC signatures
(v3) of all CA-CRC samples. A, Relative
contribution heatmap. B, Cosine
similarity heatmap. Mutation rate over
10/Mb identifies hypermutated
samples [Color figure can be viewed at
wileyonlinelibrary.com]
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specified otherwise. For LS tumors, raw sequence data based on CCP
panel (n = 578 genes) was available from a previous investigation16
and was reanalyzed by the same protocol used for the Pan-cancer
data (see Materials and Methods) to enable comparison with CA-CRC
results. For CA-CRC, CCP panel targets were extracted from the Pan-
cancer sequencing data for the purposes of comparison.
All LS tumors showed MSI-high and were hypermutated (>10
nonsynonymous somatic mutations/Mb). The overall mutation rate
(VarScan2 somatic P value <.01) was significantly higher in
LS-associated tumors than in CA-CRC, with averages of 208.5 muta-
tions/Mb (median 175.6/Mb, range 15.8-528.8/Mb) and 14.4 muta-
tions/Mb (median 5.5/Mb, range 2.8-108.8/Mb), respectively
(P = 2.3E-12; Table 2). The same applied to high-frequency mutations
(VAF 25% or higher), with the average and median numbers of 17.4
mutations/Mb and 12.4 mutations/Mb in LS tumors vs 2.1 mutations/
Mb and 0.75 mutations/Mb in CA-CRC tumors (P = 5.6E-12). Among
genes most often affected by high-frequency somatic mutations
(Supplementary Figure 1), TP53 showed significantly higher mutation
rates in CA-CRC than LS tumors (14/27, 52% vs 3/28, 11%,
P = .0013; Supplementary Figure 1A; Table 2). Conversely, mutations
of APC were significantly more common in LS tumors compared to
CA-CRC (16/28, 57% vs 3/27, 11%, P = .0005; Table 2). By mutation
type (truncating vs nontruncating), truncating (ie, nonsense or frame-
shift) mutations were clearly more common in LS-associated tumors
(Supplementary Figure 1C) compared to CA-CRC (Supplementary
Figure 1B), consistent with MSI statuses (100% of LS and 4% of
CA-CRC tumors had MSI; Table 2).
Somatic mutational signatures for the individual LS tumors are
depicted in Supplementary Figure 2. LS tumors clustered into two
major groups; signature profiles were evidently more uniform than
between the subgroups of CA-CRC samples. In LS, the overall number
of nonsynonymous mutations (below vs above 100 mutations/Mb)
appeared to contribute to the pattern of sample clustering. The CIMP
status seemed randomly distributed across the LS clusters (the same
applied to CA-CRC tumors; Figure 3). Mutation signatures of
LS-associated adenomas and carcinomas were very similar. Signatures
1 (aging-associated, “clock-like”), 4 (tobacco smoking-associated),
6 (MMR deficiency-associated), 10b (POLE-proofreading domain
mutation-associated) and 4619,29,30 (see also https://cancer.sanger.ac.
uk/cosmic/signatures/SBS/) were well represented in the LS tumors
(Figure 4B; Supplementary Figure 2). When compared to hyper-
mutated MSS CA-CRCs (n = 9), LS tumors (n = 28, all hypermutated)
showed clearly distinctive mutation signatures (Figure 4B; Supplemen-
tary Figure 3–A-C), compatible with different disease etiologies.
4 | DISCUSSION
Patients with UC like those with LS are predisposed to early onset
CRC. Severity,31 duration32 and extent33,34 of inflammation increase
(A) (B)
F IGURE 4 Relative contribution of mutational signatures, comparing the five largest contributors selected from each group. A, Top five
signatures in hypermutated MSS CA-CRC (n = 9) and nonhypermutated MSS CA-CRC (n = 17) totaling eight signatures. B, Top five signatures in
LS tumors (hypermutated MSI) (n = 28) and hypermutated MSS CA-CRC (n = 9) totaling nine signatures [Color figure can be viewed at
wileyonlinelibrary.com]
3004 MÄKI-NEVALA ET AL.
the risk of CRC in UC patients. In LS, inherited MMR deficiency con-
stitutes the main cancer susceptibility factor5 and results in immuno-
activation9; some observations suggest an even more primary
tumorigenic role for immunological alterations in LS.35 Contrary to
100% of LS tumors, only one CA-CRC (4%) showed MSI in our investi-
gation. The low frequency of MSI high in CA-CRCs complies with pub-
lished studies (9%-17%).23,36,37 MSI coincided with elevated rates of
somatic nonsynonymous mutations in the single MSI CA-CRC tumor
(84.8 mutations/Mb; Figure 3) and even more so in the LS tumors
(average 208.5 mutations/Mb); among the latter, association with
truncating mutations was also evident (Supplementary Figure 1C).
MMR, CIMP, BRAF Val600Glu and KRAS mutation statuses are
widely used molecular classifiers of CRC, where MSI is associated
with favorable prognosis and BRAF mutation with poor prognosis,
whereas the clinical significance of CIMP and KRAS mutations is less
consistent.38,39 Our CA-CRCs did not essentially differ from sporadic
CRCs38,39 or UC-associated CRCs40 from published studies with
respect to these characteristics. As far as CIMP status is concerned,
reported frequencies of CIMP(+) vary a lot, even when the same clas-
sification system (such as the Weisenberger criteria) is used. This
likely reflects the technique chosen (eg, MS-MLPA vs quantitative
real-time PCR) and the cutoff values set for hypermethylation. We
observed CIMP(+) prevalence of 41% in CA-CRC tumors (and a com-
parable frequency for LS tumors, 39%), whereas real-time PCR-based
studies have arrived at considerably lower frequencies (5%-17%).40,41
Our CIMP scoring method corresponds to that described in Berg
et al42 and the CIMP(+) frequency we observed for CA-CRCs falls
within the range obtained for sporadic CRCs (24%-45% depending on
the stringency of criteria).42
The broader somatic mutational profiles based on 999 cancer-
relevant genes divided our CA-CRCs into three subgroups, consisting
of hypermutated MSI tumors (1/27, 4%), hypermutated MSS tumors
(9/27, 33%), and nonhypermutated MSS tumors (17/27, 63%). The
strongest support comes from mutational signatures that reflect the
underlying pathophysiologic processes.29 Hypermutated MSI and
nonhypermutated MSS subgroups are already evident from previous
studies that addressed somatic mutation patterns in CA-CRC by panel
or exome sequencing.23,26,27 To our knowledge, a significant subgroup
that is MSS, yet hypermutated, has not been pointed out among MSS
CA-CRCs before. Identifying this subgroup in clinical practice might
open a better targeted therapeutic selection with immune checkpoint
inhibitors despite the lack of MSI. Tumors associated with polymerase
proofreading defects43 may be hypermutated in the absence of MSI.
In our CA-CRC series, somatic low-frequency mutations in the POLD1
and/or POLE genes were detected in four tumors, including the single
hypermutated MSI tumor, two hypermutated MSS tumors and one
nonhypermutated MSS tumor (Supplementary Table 4). None of the
mutations affected the proofreading domain and none of the tumors
was associated with any (notable) Signature 10b (the hallmark of POLE
proofreading domain mutations),29 arguing against functional rele-
vance of these mutations. However, the possibility that some POLD1
or POLE mutations may have contributed to hypermutability cannot
be totally excluded. Two mutations had been deposited to COSMIC
and/or ClinVar with the status of “uncertain significance” for both;
these cooccurred, although with low allele frequencies (7% for POLD1
p.Arg1079His and 6% for POLE c.5678+1G>A) in a MSS tumor with
the highest somatic mutational load (118 nonsynonymous mutations/
Mb) in our entire CA-CRC series.
Signatures 30 and 32 predominated among our hypermutated
MSS CA-CRC tumors, whereas no truly dominant single signature was
present in the nonhypermutated MSS subgroup (Figures 3 and 4). Sig-
nature 30 has been linked to inactivating mutations of NTHL1 under-
lying hereditary base excision repair deficiency.44 Our sequencing
panel included the NTHL1 gene, but no somatic mutations were
found. Signature 32 is associated with transcriptional bias of C>T
mutations with abundance of G mutations on the untranscribed
strands, and its proposed etiology is linked to immunosuppression
induced by azathioprine treatment. Many of our CA-CRC patients had
a history of immunosuppression medication. Recently, Inman et al
found Signature 32 in cutaneous squamous cell carcinoma, and its
association with Signatures 11 and 30.45 This pattern was evident in
our hypermutated MSS CA-CRC samples as well (Figures 3 and 4).
Signature 11 has been linked to alkylating agents; damage caused by
these agents is corrected by the MGMT enzyme that is prone to fre-
quent inactivation by promoter methylation in CA-CRCs.46
Analysis of selected candidate pathways as mutational targets
offered some insights into possible mechanisms that might underlie
hypermutated MSS CA-CRCs. Somatic mutations of DNA repair genes
(Supplementary Table 5A) and those of Wnt signaling genes
(Supplementary Table 5B) were significantly more prevalent in the
hypermutated MSS group compared to the nonhypermutated
CA-CRCs. While the cause and effect relationships are unknown, it is
possible that disruption of DNA repair and/or Wnt signaling functions
contributed to the elevated overall mutation rates seen in the hyper-
mutated MSS CA-CRC group.
COSMIC signatures19,29 are based on single-base substitutions.
To evaluate the role of copy number alterations in the pathogenesis
of CA-CRC, Baker et al23 used exome sequencing supplemented with
SNP arrays and fluorescent in situ hybridization and found that copy
number alterations started to increase at the transition from low-
grade to high-grade dysplasia. Our approach did not allow a reliable
detection of copy number alterations, which is a limitation of our
investigation. TP53 mutations, a surrogate for copy number status,
were similarly distributed between hypermutated and non-
hypermutated MSS CA-CRCs (Supplementary Table 4).
Contrary to sporadic CRCs, TP53 mutations are proposed to
occur as initiating events and APC mutations as late events in
CA-CRC-related carcinogenesis.26,47 The high VAFs and involvement
in most CA-CRC tumors characteristic of TP53 mutations we
observed (Figure 1) is consistent with this notion. It has been
proposed that TP53 mutations in CA-CRC occur at different hotspots
compared to sporadic CRC, although in both tumor types, DNA bind-
ing domain is the most common target of mutations.23,26 As demon-
strated in Figure 2, the locations of TP53 mutations in our CA-CRCs
were largely concordant with those reported in recent literature.23-27
Yaeger et al27 additionally found MYC to be more frequently mutated
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in CA-CRC compared to sporadic cases, but we found only one case
with a MYC mutation. Among CA-CRCs, APC mutations occurred
exclusively in the hypermutated MSS subgroup (Supplementary
Tables 4 and 5B). The relatively low overall prevalence of high-
frequency mutations in APC (Figure 1A; Supplementary Table 4) and
the fact that all samples exhibiting APC mutations harbored more than
one APC mutation (Supplementary Table 4) are in agreement with the
suggestion of APC mutations occurring late in CA-CRC-associated
tumorigenesis.
Compared to hypermutated MSS CA-CRCs, mutational signatures
of LS tumors were strikingly different (Figure 4B; Supplementary
Figure 3A-C; Table 2). Signature 1 was prominent in LS tumors; this
signature has been proposed to be associated with an endogenous
mutational process of deamination of 50 methylcytosine to thymine
and is characterized by C>T transitions at methylated NpCpG sites.
Formalin fixation and older age may increase this process.29 However,
the age range of our LS patients with a strong Signature 1 in tumor
samples was 31 to 74 years, and there was no positive correlation
between age and contribution of Signature 1 (r2 = −0.17; P = .722).
Among MMR deficiency-associated signatures, Signature 6 was prev-
alent among LS tumors (Supplementary Figure 2), whereas the single
MSI CA-CRC sample exhibited Signatures 21, 15 and 26 (Figure 3).
This agrees with the notion that Signature 6 is mainly associated with
germline mutations of MMR genes, whereas Signatures 15, 20 and
26 are characteristic of somatic MMR deficiency.48
In conclusion, the patterns of somatic alterations stratified
CA-CRCs into three subgroups: hypermutated MSI (4%), hypermutated
MSS (33%) and nonhypermutated MSS (63%). Our observation of a
significant hypermutated subgroup among MSS CA-CRCs, not
explained by polymerase proofreading defects or defects of other cur-
rently known genes, is novel. Further studies with larger sample sets
are necessary to confirm the proportional relationships of these sub-
groups. Molecular pathways that were differentially affected between
the three CA-CRC subgroups (such as MMR and other DNA repair
mechanisms; Supplementary Tables 4 and 5) can have prognostic or
therapeutic significance in CA-CRC in analogy to their established rele-
vance in sporadic CRCs or LS.39,49
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